Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 47 Carcinoma, Hepatocellular 29 Neoplasms 18 Neoplasm Metastasis 14 Melanoma 14 Stomach Neoplasms 13 Esophageal Neoplasms 13 Colorectal Neoplasms 12 Nasopharyngeal Carcinoma 10 Esophageal Squamous Cell Carcinoma 10 Triple Negative Breast Neoplasms 9 Head and Neck Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 8 Recurrence 8 Breast Neoplasms 8 Rectal Neoplasms 7 Pancreatic Neoplasms 7 Lung Neoplasms 7 Carcinoma, Renal Cell 7 Biliary Tract Neoplasms 7 Small Cell Lung Carcinoma 6 Colonic Neoplasms 5 Cholangiocarcinoma 5 Sarcoma 4 Ovarian Neoplasms 4 Locally Advanced Rectal Cancer 4 Liver Neoplasms 4 Advanced NSCLC 4 Urinary Bladder Neoplasms 3 Prostatic Neoplasms 3

Interventions

Etoposide 3 Carboplatin 3 Paclitaxel 2 sintilimab 1 pembrolizumab 1 olaparib 1 ceralasertib 1 atezolizumab 1 apatinib 1 anlotinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC × Immune Checkpoint Inhibitors × Clear all

NCT07110103 2026-02-27

JACKPOT38

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡